Petros Pharmaceuticals, Inc. (NASDAQ:PTPI – Get Free Report) shares traded down 5.8% during trading on Friday . The company traded as low as $0.32 and last traded at $0.33. 6,130,722 shares were traded during mid-day trading, an increase of 1,045% from the average session volume of 535,337 shares. The stock had previously closed at $0.35.
Petros Pharmaceuticals Stock Down 5.8 %
The firm’s 50 day moving average price is $0.32 and its two-hundred day moving average price is $0.37. The company has a market capitalization of $3.30 million, a price-to-earnings ratio of -0.07 and a beta of 1.99. The company has a current ratio of 0.85, a quick ratio of 0.74 and a debt-to-equity ratio of 1.58.
Petros Pharmaceuticals Company Profile
Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
Recommended Stories
- Five stocks we like better than Petros Pharmaceuticals
- Where Do I Find 52-Week Highs and Lows?
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Golden Cross Stocks: Pattern, Examples and Charts
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- What is the Nikkei 225 index?
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Petros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
